
News|Articles|February 1, 2010
Formulary Digital Edition February 2010
Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis; Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes; and Agents in late-stage development for renal diseases
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
House passes funding bill that includes PBM reform
2
Medicare’s first-year payments for social needs showed high use by primary care but many claims were denied
3
A conversation about improving PrEP uptake in New York City with Emma Kaplan-Lewis, M.D., clinical quality director for HIV, hepatitis and sexual health services at NYC Health + Hospitals
4
Congress challenges health insurers saying they put profits over patients
5































